Methods of treating type I diabetes by blocking VEGF-mediated activity

Details for Australian Patent Application No. 2005267741 (hide)

Owner Regeneron Pharmaceuticals, Inc.

Inventors Sleeman, Mark, W.; Li-Hsien, Wang; Wiegand, Stanley, J.; Hsin, Chieh, Lin; Jingtai, Cao

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2005267741

PCT Pub. Number WO2006/015297

Priority 60/592,628 30.07.04 US

Filing date 29 July 2005

Wipo publication date 9 February 2006

International Classifications

A61K 38/00 (2006.01) Medicinal preparations containing peptides

A61K 38/17 (2006.01) Medicinal preparations containing peptides - from animals

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

C07K 19/00 (2006.01) Hybrid peptides

Event Publications

21 December 2006 PCT application entered the National Phase

  PCT publication WO2006/015297 Priority application(s): WO2006/015297

24 February 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005267748-Amorphous cell delivery vehicle treated with physical/physicochemical stimuli

2005267739-Systems and methods for providing dynamic price axes in featured user interfaces